NCT03456544

Vancomycin-Associated Acute Kidney Injury: A Cross-Sectional Study From a Multi- Center in China

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 10,000 (estimated)
• Sponsor: Peking University First Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study was to investigate the current situation of vancomycin (VAN)-associated acute kidney injury (VA-AKI) in China and identify the risk factors for VA-AKI, as well as to comprehensively examine the risk related to concurrent drug use. Further, the investigators assessed the outcomes of patients who developed VA-AKI and the risk factors for these outcomes. Finally, the investigators aimed to provide suggestions for improving the prevention and treatment of VA-AKI in China.

Conditions

• Vancomycin
• Staphylococcal Infections
• Adverse Effect
• Acute Kidney Injury
• Cross-sectional Study

Interventions

Type	Name	Description
DRUG	Vancomycin	Patients who have vancomycin associated acute kidney injury will be in the Van-AKI group, and those who don't have vancomycin associated acute kidney injury will be in the none VAN-AKI group.

Timeline

• Start date: 2018-10-31
• Primary completion: 2019-10-31
• Completion: 2019-12-31
• First posted: 2018-03-07
• Last updated: 2019-08-28

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study